Browsing by Author Cooper, Mark E.

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
or enter first few letters:  
Showing results 1 to 3 of 3
Issue DateTitleAuthor(s)Citation
2003A breaker of advanced Glycation end products attenuates diabetes-induced myocardial structural changesTwigg, Stephen; Burns, Wendy C; Burrell, Louise M; Candido, Riccardo; Cooper, Mark E.; Dean, Rachael G.; Forbes, Josephine M; Ritchie, Rebecca H; Thallas, Vicki; Thomas, Merlin C.; Tikellis, Christos; Central Clinical School: MedicineA breaker of advanced Glycation end products attenuates diabetes-induced myocardial structural changes, Circulation Research, vol.92,(7),2003,pp 785-792
2015Dipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA–T2D™ trialPerkovic, Vlado; Cescutti, Jessica; Cooper, Mark E.; et al, Various; Gordat, Maud; Groop, Per-Henrik; Haneda, Masakazu; Hocher, Berthold; Schernthaner, Guntram; Sharma, Kumar; The George Institute for Global HealthDipeptidyl peptidase-4 inhibition with linagliptin and effects on hyperglycaemia and albuminuria in patients with type 2 diabetes and renal dysfunction: Rationale and design of the MARLINA–T2D™ trial, Diabetes and Vascular Disease Research, vol.12, 6, 2015,pp 455-462
2010E-Cadherin Expression Is Regulated by miR-192/215 by a Mechanism That Is Independent of the Profibrotic Effects of Transforming Growth Factor-BTwigg, Stephen; Burns, Wendy C; Cooper, Mark E.; Goodall, Gregory J.; Herman-Edelstein, Michal; Jandeleit-Dahm, Karin A; Kantharidis, Phillip; Koh, Philip; Saleem, Moin; Wang, Bo; Watson, Anna; Central Clinical School: MedicineE-Cadherin Expression Is Regulated by miR-192/215 by a Mechanism That Is Independent of the Profibrotic Effects of Transforming Growth Factor-B, Diabetes, vol.59, 7,pp 1794-1802